Suresnes, March 6, 2023 – 8 a.m. CET – Neovacs (Euronext Growth Paris: ALNEV) announces the availability of a new scientific publication in the journal
Allergy, European Journal of Allergy and Clinical Immunology
titled “Vaccine Targeting Human IL-4 and IL-13 Protects Against Asthma in Humanized Mice
[1]
“.
online article
Néovacs, in collaboration with Inserm via two research teams led by Laurent Reber (Infinity Institute, Toulouse) and Pierre Bruhns (Inserm, Institut Pasteur), have just published in the prestigious journal
allergy
(a leading journal in the field of allergy and clinical immunology) new work demonstrating the efficacy of a vaccine targeting interleukin-4 (IL-4) and interleukin-13 (IL-13 ) in a model of asthma in “humanized” mice.
Asthma is a chronic disease that affects approximately 4 million people in France and 340 million worldwide. Allergic asthma is characterized by inflammation of the bronchi and respiratory discomfort caused by the inhalation of allergens, most often dust mites. This exposure to dust mites and other allergens induces an overproduction of IL-4 and IL-13 in the airways. This then leads to a cascade of reactions leading to hyperreactivity of the airways, overproduction of mucus and eosinophilia (too high level of white blood cells called eosinophils in the airways).
Neovacs and Inserm researchers have demonstrated that a conjugate vaccine, called Kinoid®, targeting human IL-4 and IL-13 can neutralize the activity of these two proteins in allergic asthma. In particular, the Kinoid vaccine made it possible to block bronchial hyperreactivity, overproduction of mucus and eosinophilia in a model of allergic asthma in “humanized” mice expressing human IL-4 and IL-13 at the place of the respective murine proteins.
Vincent Serra, scientific director of Neovacs declares: “
This breakthrough represents a major step in the development of our Kinoid vaccine, as it provides direct evidence of the efficacy of a human vaccine in neutralizing human interleukins in asthma, paving the way towards the establishment of a Phase I/IIa clinical trial. Our teams have already been working for several months on the vaccine manufacturing process under Good Manufacturing Practice to achieve this.
»
As a reminder, Neovacs is currently developing a Kinoid vaccine targeting simultaneously IL-4 and IL-13 in the context of asthma and atopic dermatitis.
In the context of food allergies, Neovacs is simultaneously developing the Kinoid vaccine targeting IL-4 and IL-13 and a Kinoid vaccine targeting immunoglobulin E (IgE).
These Kinoid® will be tested as part of a Phase I/IIa trial after regulatory approval for which Neovacs has secured cash of €15 million.
As a reminder, in 2022, Néovacs signed two worldwide exclusive license agreements negotiated with the private subsidiary of Inserm (Inserm Transfert), on behalf of its historical academic partners, Inserm and the Institut Pasteur, on families of strategic patents. These licenses relate to patents defining and protecting clinical development work and the marketing of candidate vaccines in the areas of asthma and food allergies. Through these new agreements, the company secures the exclusive rights to exploit these inventions.
Neovacs also expanded its technological potential by announcing, in October 2022, the filing of an international patent application around its new messenger RNA (mRNA) platform in the field of autoimmune and inflammatory diseases, particularly around allergies. The invention thus protected relates to a therapeutic vaccine and its use for treating pathological effects associated with aberrant IL-4 and IL-13 expression, in particular asthma, food allergies, venom responses and occurrence of anaphylactic shock, atopic dermatitis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). This vaccine, easy to produce, would complement the use of Kinoid products.
ABOUT NEOVACS
Neovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, makes it possible to induce a polyclonal immune response, applicable in several indications. Neovacs has developed IFNα Kinoid for the treatment of lupus in a phase IIb clinical study. The main study has been completed, the full results were presented on the 13
th
2019 international lupus congress. The Company has also completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this “Kinoid® approach” is to enable patients to better tolerate a lifelong treatment which would be more effective, well tolerated and very flexible in its administration.
For more information :
www.neovacs.fr
Jérôme FABREGUETTES-LEIB | Deborah SCHWARTZ |
[1]
Original title :
A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
mm1plMhmYmnHx2xvlphsb2lkm2dmm2HIaWWcmmluZpuWbmlmymuUm8mcZnBpnG5u
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/78798-nvcs_cp_publication_allergy_2023_vdef.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com